US FDA approves first mRNA flu shot from Moderna

The US Food and Drug Administration (FDA) has approved Moderna's first mRNA-based flu vaccine. This was reported by Qazaqyia.kz citing Reuters.

This decision is a significant step in the application of mRNA technology to combat traditional diseases such as influenza. Moderna's vaccine uses an mRNA molecule that encodes a viral protein, stimulating the immune system to produce antibodies against the virus.

The FDA approval demonstrates the expansion of mRNA technology, successfully used in COVID-19 vaccines during the pandemic, to other diseases. Experts believe this could increase the effectiveness of flu vaccination and accelerate the process of annual vaccine updates.

Moderna stated that in clinical trials, the vaccine showed high efficacy and a good safety profile. The vaccine is expected to hit the market in the coming months, though an exact date has not yet been announced.

This news has generated great interest among healthcare professionals and the public, as influenza infects millions of people worldwide each year and causes hundreds of thousands of deaths.